Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PARG | Q86W56 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9173527 | 0.85 | KMT2A (0.67) | SMN1; SMN2PKMKMT2AALDH1A1PARG | |
| SCHEMBL1876581 | 0.81 | IDO1 (0.70) | IDO1SMN1; SMN2CYP2C19MAPTTSHR | |
| SCHEMBL4319739 | 0.79 | IDO1 (0.68) | IDO1SMN1; SMN2CYP2C19PKMKMT2A | |
| SCHEMBL1581598 | 0.77 | CYP2C19 (0.67) | IDO1SMN1; SMN2CYP2C19PKMALDH1A1 | |
| SCHEMBL6290759 | 0.77 | MEN1 (0.74) | IDO1SMN1; SMN2CYP2C19PKMKMT2A | |
| SCHEMBL7011027 | 0.77 | ALDH1A1 (0.74) | IDO1SMN1; SMN2CYP2C19PKMKMT2A | |
| SCHEMBL10638309 | 0.77 | CYP2C19 (0.67) | IDO1SMN1; SMN2CYP2C19PKMKMT2A | |
| SCHEMBL2850010 | 0.76 | CYP19A1 (0.72) | IDO1SMN1; SMN2CYP2C19PKMKMT2A | |
| SCHEMBL18725052 | 0.76 | KEAP1 (0.71) | IDO1SMN1; SMN2CYP2C19MAPT | |
| SCHEMBL15067289 | 0.76 | IDO1 (0.64) | IDO1SMN1; SMN2CYP2C19PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010111653-A2 | MODULATING IRES-MEDIATED TRANSLATION | THE UAB RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | EIF2AK2, EIF4EBP1, EIF4E | IDO1 3622/4885SMN1; SMN2 1695/4885CYP2C19 4873/4885 |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | EIF2AK2, RPS25, RPL35 | IDO1 3699/4885SMN1; SMN2 1417/4885CYP2C19 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.